» Articles » PMID: 3733868

6-mercaptopurine: High-dose 24-h Infusions in Goats

Overview
Specialty Oncology
Date 1986 Jan 1
PMID 3733868
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

In vitro investigations have indicated the need for both prolonged exposure to 6-mercaptopurine (6MP) and the use of high concentrations to achieve maximal cell kill. After the customary oral administration the bioavailability of 6MP appeared to be low, and i.v. bolus injections resulted in short-lived high concentrations of 6MP, so prolonged infusions seemed rational. To test the feasibility of this approach 24-h infusions were given to goats. We used our improved HPLC method to quantitate 6MP and 6MP riboside (6MPR) in plasma, CSF, and urine. The concentrations of 6MPR were in excess of those of 6MP. Since 6MPR can easily be converted to 6MP, 6MPR acts as a depot for 6MP. Penetration of both 6MP and 6MPR into CSF was excellent. Of the total dose administered, 38% to 68% could be accounted for in the urine, with about equal amounts of 6MP and 6MPR. At doses of 20 and 10 mg kg-1 h-1 total concentrations of 6MP and 6MPR in excess of 100 microM were reached during 24-h infusions. However, all three experimental animals died due to toxicity. A dose of 2 mg kg-1 h-1 was tolerated; the total steady state concentration of 6MP and 6MPR in two experiments was about 10 microM. We conclude that the prolonged infusion of 6MP is feasible, and in view of the excellent penetration of 6MP and 6MPR into CSF, studies using prolonged infusions of thiopurines are warranted in man.

Citing Articles

6-Thioguanine: high-dose 2-H infusions in goats.

Schouten T, De Abreu R, SCHRETLEN E, Van Leeuwen M, van Baal J, de Vaan G J Cancer Res Clin Oncol. 1985; 110(2):115-8.

PMID: 4044625 DOI: 10.1007/BF00402722.


6-Mercaptopurine in cerebrospinal fluid during oral maintenance therapy of children with acute lymphoblastic leukemia.

Hayder S, Lafolie P, Bjork O, AHSTROM L, Peterson C Med Oncol Tumor Pharmacother. 1988; 5(3):187-9.

PMID: 3166086 DOI: 10.1007/BF02986443.

References
1.
Matsumura S, Hoshino T, Weizsaecker M, Deen D . Paradoxical behavior of 6-mercaptopurine as a cytotoxic agent: decreasing cell kill with increasing drug dose. Cancer Treat Rep. 1983; 67(5):475-80. View

2.
Schouten T, De Abreu R, de Bruyn C, van der Kleijn E, Oosterbaan M, SCHRETLEN E . 6-mercaptopurine: pharmacokinetics in animals and preliminary results in children. Adv Exp Med Biol. 1984; 165 Pt B:367-70. DOI: 10.1007/978-1-4757-0390-0_69. View

3.
Nelson J, Cserr H, Chu S . Distribution of 6-mercaptopurine ribonucleoside and other purine analogs to brain. Cancer Res. 1974; 34(8):1889-91. View

4.
MELLETT L . Physicochemical considerations and pharmacokinetic behavior in delivery of drugs to the central nervous system. Cancer Treat Rep. 1977; 61(4):527-31. View

5.
King M, Honeysett J, Howell S . Regulation of de novo purine synthesis in human bone marrow mononuclear cells by hypoxanthine. J Clin Invest. 1983; 72(3):965-70. PMC: 1129262. DOI: 10.1172/JCI111068. View